Cargando…

CDK9 inhibitors in multiple myeloma: a review of progress and perspectives

Currently, multiple myeloma is not yet considered a curable disease. Despite the recent advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 inhibitors emerged as a suitable agent to overcome resistance and prolong survival in patients with poor diagnoses. Downre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borowczak, Jędrzej, Szczerbowski, Krzysztof, Ahmadi, Navid, Szylberg, Łukasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800928/ https://www.ncbi.nlm.nih.gov/pubmed/35092513 http://dx.doi.org/10.1007/s12032-021-01636-1

Ejemplares similares

The Prognostic Role of CDK9 in Bladder Cancer
por: Borowczak, Jędrzej, et al.
Publicado: (2022)

The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma
por: Borowczak, Jędrzej, et al.
Publicado: (2022)

The Role of Inflammatory Cytokines in the Pathogenesis of Colorectal Carcinoma—Recent Findings and Review
por: Borowczak, Jędrzej, et al.
Publicado: (2022)

TOLLIP Protein Expression Predicts Unfavorable Outcome in Renal Cell Carcinoma
por: Kowalewski, Adam, et al.
Publicado: (2022)

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
por: Natoni, Alessandro, et al.
Publicado: (2013)

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Expression of Matrix Metalloproteinase-2/9 and Tissue Inhibitor of Metalloproteinase-1/2 as Predictive Factors in Oropharyngeal Squamous Cell Carcinoma
por: Burduk, Pawel-Krzysztof, et al.
Publicado: (2019)

MYC inhibitors in multiple myeloma
por: Martínez-Martín, Sandra, et al.
Publicado: (2021)

Role of Interleukins and New Perspectives in Mechanisms of Resistance to Chemotherapy in Gastric Cancer
por: Janiczek-Polewska, Marlena, et al.
Publicado: (2022)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
por: Nishida, Hiroko
Publicado: (2021)

Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review
por: Ismail, Nor Hayati, et al.
Publicado: (2023)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Diagnosis of Hirschsprung's disease with particular emphasis on histopathology. A systematic review of current literature
por: Szylberg, Łukasz, et al.
Publicado: (2014)

Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
por: Sanz-Solas, Antonio, et al.
Publicado: (2023)

Consolidation in multiple myeloma – current status and perspectives
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2014)

Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma
por: Murdaca, Giuseppe, et al.
Publicado: (2021)

The Role of Epigenetics in the Development and Progression of Multiple Myeloma
por: Ismail, Nor Hayati, et al.
Publicado: (2022)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Targeting CDK9 for the Treatment of Glioblastoma
por: Ranjan, Alice, et al.
Publicado: (2021)

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
por: Xiao, Lanshu, et al.
Publicado: (2023)

Identification of a novel CDK9 inhibitor targeting the intramolecular hidden cavity of CDK9 induced by Tat binding
por: Asamitsu, Kaori, et al.
Publicado: (2022)

Progress in multiple myeloma
por: Munker, Reinhold, et al.
Publicado: (2019)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
por: Kryštof, Vladimír, et al.
Publicado: (2012)

Recent advances in multiple myeloma: a Korean perspective
por: Hong, Junshik, et al.
Publicado: (2016)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Progress in the identification of gene mutations involved in multiple myeloma
por: Hu, Ying, et al.
Publicado: (2019)

The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
por: García-Ortiz, Almudena, et al.
Publicado: (2021)

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma
por: Chang-Yew Leow, C, et al.
Publicado: (2013)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dj0gcsi4c27cv1q999iljt93j7